NCT05003531View on ClinicalTrials.gov

A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

September 23, 2021

Primary Completion Date

March 25, 2022

Study Completion Date

January 17, 2023

Conditions
Psoriasis
Interventions
DRUG

IBI112 dose 2

Participants will receive placebo or dose 2 IBI112 SC

DRUG

IBI112 dose 4

Participants will receive placebo or dose 4 IBI112 SC

DRUG

IBI112 dose 1

Participants will receive placebo or dose 1 IBI112 SC

DRUG

IBI112 dose 3

Participants will receive placebo or dose 3 IBI112 SC

DRUG

placebo

Participants will receive placebo SC

Trial Locations (1)

100044

PeKing University People's Hostpital, Beijing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT05003531 - A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis | Biotech Hunter | Biotech Hunter